U.S., June 6 -- ClinicalTrials.gov registry received information related to the study (NCT07006727) titled 'Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors' on May 16.
Brief Summary: The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of [225Ac]Ac-ETN029 and the safety and imaging properties of [111In]In-ETN029 in patients aged >= 18 years with locally advanced or metastatic DLL3 positive cancers.
Study Start Date: July 15
Study Type: INTERVENTIONAL
Condition:
Small Cell Lung Carcinoma
Large Cell Neuroendocrine Carcinoma of the Lung
Neuroendocrine Prostate Cancer
Gastroenteropancreatic Neuroendocrine Carcinoma
Intervention:
DRUG: 225Ac-ETN029
...